Editorial: Stem cell funding is venture capital
By San Francisco Examiner,
San Francisco Examiner
| 08. 30. 2005
Last year's predictions of the benefits California would derive from approving Proposition 71 and funding stem cell research were overly optimistic, a recent study proclaimed.
The report, funded by universities and a biomedical trade association, concluded that while the state would benefit from new jobs, tax revenues and improvements to public health, requiring companies to pay for their use of research funding would stifle the participation of businesses.
In a sense, those using the report to oppose measures now under consideration in the state Legislature to codify how California will benefit from stem cell research are saying they want to consider billions of dollars in taxpayers' money not as a loan for investment purposes _ venture capital _ but instead as an outright gift.
Including interest, state taxpayers will likely end up paying $6 billion or more to repay the $3 billion in bonds.
The stem cell institute is scheduled to disburse its first grants soon, so let's be clear: Prop. 71's $3 billion in public money was not meant to be a gift. It was meant to be an...
Related Articles
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...
By Adam Zewe, MIT News | 02.07.2024
A tiny device built by scientists at MIT and the Singapore-MIT Alliance for Research and Technology could be used to improve the safety and effectiveness of cell therapy treatments for patients suffering from spinal cord injuries.
In cell therapy, clinicians...